Vimarsana
Biggest News Aggregation in the World

Page 10 - Solid Biosciences Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Biosciences Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Biosciences Inc Today - Breaking & Trending Today

Solid Biosciences Inc. (NASDAQ:SLDB) to Post Q3 2023 Earnings of ($1.05) Per Share, Leerink Partnrs Forecasts - Vimarsana News

Solid Biosciences Inc. (NASDAQ:SLDB) to Post Q3 2023 Earnings of ($1.05) Per Share, Leerink Partnrs Forecasts

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Stock analysts at Leerink Partnrs boosted their Q3 2023 earnings per share (EPS) estimates for shares of Solid Biosciences in a report released on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($1.05) for the quarter, […]

Source: wkrb13.com
Q3 2023 EPS Estimates for Solid Biosciences Inc. Lifted by Analyst (NASDAQ:SLDB) - Vimarsana News

Q3 2023 EPS Estimates for Solid Biosciences Inc. Lifted by Analyst (NASDAQ:SLDB)

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Equities research analysts at Leerink Partnrs raised their Q3 2023 earnings per share (EPS) estimates for Solid Biosciences in a research note issued to investors on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($1.05) per share for […]

North American Morning Briefing : Treasury Yields -2- - Today - Vimarsana News

North American Morning Briefing : Treasury Yields -2- - Today

NantHealth Inc is expected to report for 2Q. Nicholas Financial is expected to report for 1Q. Orbital Infrastructure Group Inc is expected to report for 2Q. Outlook Therapeutics Inc ... -Today at 06:23 am- MarketScreener

Solid Biosciences Provides Second Quarter Business Update and Financial Results - Vimarsana News

Solid Biosciences Provides Second Quarter Business Update and Financial Results

– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy – – Executed licensing agreement for development and... -Today at 04:18 pm- MarketScreener

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates - Vimarsana News

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Source: yahoo.com